{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:32:05Z","timestamp":1792794725362,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Hemophagocytic lymphohistiocytosis is a rare, potentially fatal syndrome of immune hyperactivation. Here we describe a ganglionar tuberculosis evolving to hemophagocytic lymphohistiocytosis following adjuvant immunotherapy in a melanoma patient.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>A 76-year-old Caucasian male with melanoma started with fever, diffuse petechiae, splenomegaly, anemia, thrombocytopenia, hypofibrinogenemia, and hyperferritinemia 2\u00a0months following completion of adjuvant treatment with nivolumab. Positron emission tomography scan showed significant hypermetabolism in cervical, supraclavicular, mediastinal, and abdominal lymph nodes. Bone marrow aspiration demonstrated no alterations, except for a hypercellular pattern. Dexamethasone and intravenous immunoglobulin were started owing to suspicion of hemophagocytic lymphohistiocytosis. Core biopsy of the infracarinal lymph node revealed a chronic granulomatous inflammation and caseous necrosis, with positivity for<jats:italic>Mycobacterium\u00a0tuberculosis<\/jats:italic>by polymerase chain reaction, and treatment for ganglionar tuberculosis was started.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This case highlights the challenges involving programmed cell death 1 blockade in high-risk melanoma, in which infections, lymphoproliferative disorders, and sarcoidosis can mimic disease progression and trigger immune-related adverse events.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13256-021-02900-8","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T23:05:11Z","timestamp":1625699111000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Ganglionar tuberculosis infection evolving to hemophagocytic lymphohistiocytosis after anti-programmed cell death 1 treatment for high-risk melanoma: a\u00a0case report"],"prefix":"10.1186","volume":"15","author":[{"given":"Cesar M.","family":"Costa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiza L.","family":"Gadotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Seiwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra C. R.","family":"Salgues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Ganem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen C. T.","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Uip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celso","family":"Arrais-Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo R.","family":"Munhoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,8]]},"reference":[{"key":"2900_CR1","unstructured":"Cancer. Net. Melanoma: Statistics. Amer Soci of Clin Oncol (ASCO). 2021; https:\/\/www.cancer.net\/cancer-types\/melanoma\/statistics."},{"key":"2900_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/ITT.S134842","volume":"7","author":"B Domingues","year":"2018","unstructured":"Domingues B, Lopes JM, Soares P, P\u00f3pulo H. Melanoma treatment in review ImmunoTargets Ther. 2018;7:35\u201349.","journal-title":"ImmunoTargets Ther."},{"issue":"19","key":"2900_CR3","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1182\/blood-2015-01-551622","volume":"125","author":"AM Schram","year":"2015","unstructured":"Schram AM, Berliner N. How I treat hemophagocytic lymphohistiocytosis in the adult patient. Blood. 2015;125(19):2908\u201314.","journal-title":"Blood"},{"issue":"475","key":"2900_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aat2702","volume":"11","author":"DL Barber","year":"2019","unstructured":"Barber DL, Sakai S, Kudchadkar RR, Fling SP, Day TA, Vergara JA, et\u00a0al. Tuberculosis following PD-1 blockade for cancer immunotherapy. Sci Transl Med. 2019;11(475):1\u20138.","journal-title":"Sci Transl Med."},{"issue":"1","key":"2900_CR5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s40425-019-0717-7","volume":"7","author":"A Anastasopoulou","year":"2019","unstructured":"Anastasopoulou A, Ziogas DC, Samarkos M, Kirkwood JM, Gogas H. Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations. J Immunother Cancer. 2019;7(1):239. https:\/\/doi.org\/10.1186\/s40425-019-0717-7.","journal-title":"J Immunother Cancer."},{"issue":"6","key":"2900_CR6","doi-asserted-by":"publisher","first-page":"593","DOI":"10.4103\/0970-2113.168100","volume":"32","author":"S Padhi","year":"2015","unstructured":"Padhi S, Ravichandran K, Sahoo J, Varghese RG, Basheer A. Hemophagocytic lymphohistiocytosis: an unusual complication in disseminated Mycobacterium tuberculosis. Lung India. 2015;32(6):593\u2013601.","journal-title":"Lung India."},{"key":"2900_CR7","doi-asserted-by":"crossref","unstructured":"Hui YMT, Pillinger T, Luqmani A, Cooper N. Haemophagocytic lymphohistiocytosis associated with Mycobacterium tuberculosis infection. BMJ Case Rep. 2015;2015:bcr2014208220. http:\/\/casereports.bmj.com\/content\/2015\/bcr-2014-208220.abstract","DOI":"10.1136\/bcr-2014-208220"},{"issue":"1","key":"2900_CR8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s40425-018-0384-0","volume":"6","author":"A Hantel","year":"2018","unstructured":"Hantel A, Gabster B, Cheng JX, Golomb H, Gajewski TF. Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab. J Immunother Cancer. 2018;6(1):73. https:\/\/doi.org\/10.1186\/s40425-018-0384-0.","journal-title":"J Immunother Cancer."},{"issue":"1","key":"2900_CR9","doi-asserted-by":"publisher","first-page":"a017848","DOI":"10.1101\/cshperspect.a017848","volume":"6","author":"R Loddenkemper","year":"2015","unstructured":"Loddenkemper R, Lipman M, Zumla A. Clinical aspects of adult tuberculosis. Cold Spring Harb Perspect Med. 2015;6(1):a017848\u2013a017848.","journal-title":"Cold Spring Harb Perspect Med."},{"key":"2900_CR10","unstructured":"Pan American Health Organization. 2018. http:\/\/iris.paho.org\/xmlui\/handle\/123456789\/49510"},{"issue":"23","key":"2900_CR11","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1182\/blood.2018894618","volume":"133","author":"P La Ros\u00e9e","year":"2019","unstructured":"La Ros\u00e9e P, Horne A, Hines M, von Bahr GT, Machowicz R, Berliner N, et\u00a0al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019;133(23):2465\u201377.","journal-title":"Blood"},{"issue":"4","key":"2900_CR12","doi-asserted-by":"publisher","first-page":"101515","DOI":"10.1016\/j.berh.2020.101515","volume":"34","author":"G Griffin","year":"2020","unstructured":"Griffin G, Shenoi S, Hughes GC. Hemophagocytic lymphohistiocytosis: an update on pathogenesis, diagnosis, and therapy. Best Pract Res Clin Rheumatol. 2020;34(4):101515.","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"2900_CR13","doi-asserted-by":"crossref","unstructured":"Zhang Y, Liang G, Qin H, Li Y, Zeng X. Tuberculosis-associated hemophagocytic lymphohistiocytosis with initial presentation of fever of unknown origin in a general hospital: an analysis of 8 clinical cases. Medicine (Baltimore). 2017;96(16). https:\/\/journals.lww.com\/md-journal\/Fulltext\/2017\/04210\/Tuberculosis_associated_hemophagocytic.31.aspx.","DOI":"10.1097\/MD.0000000000006575"},{"issue":"11","key":"2900_CR14","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.amjmed.2014.04.034","volume":"127","author":"S Rivi\u00e8re","year":"2014","unstructured":"Rivi\u00e8re S, Galicier L, Coppo P, Marzac C, Aumont C, Lambotte O, et\u00a0al. Reactive hemophagocytic syndrome in adults: a retrospective analysis of 162 patients. Am J Med. 2014;127(11):1118\u201325. https:\/\/doi.org\/10.1016\/j.amjmed.2014.04.034.","journal-title":"Am J Med."},{"issue":"3","key":"2900_CR15","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.cmi.2017.12.003","volume":"24","author":"H Picchi","year":"2018","unstructured":"Picchi H, Mateus C, Chouaid C, Besse B, Marabelle A, Michot JM, et\u00a0al. Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment. Clin Microbiol Infect. 2018;24(3):216\u20138.","journal-title":"Clin Microbiol Infect."},{"issue":"3","key":"2900_CR16","doi-asserted-by":"publisher","first-page":"e13321","DOI":"10.1111\/dth.13321","volume":"33","author":"H Mizuta","year":"2020","unstructured":"Mizuta H, Nakano E, Takahashi A, Koyama T, Namikawa K, Yamazaki N. Hemophagocytic lymphohistiocytosis with advanced malignant melanoma accompanied by ipilimumab and nivolumab: a case report and literature review. Dermatol Ther. 2020;33(3):e13321. https:\/\/doi.org\/10.1111\/dth.13321.","journal-title":"Dermatol Ther."},{"key":"2900_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.rmed.2019.105853","volume":"1","author":"Y Im","year":"2020","unstructured":"Im Y, Lee J, Kim SJ, Koh W-J, Jhun BW, Lee S-H. Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors. Respir Med. 2020;1:161. https:\/\/doi.org\/10.1016\/j.rmed.2019.105853.","journal-title":"Respir Med."},{"issue":"7","key":"2900_CR18","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1200\/JCO.2014.55.3503","volume":"35","author":"JS Weber","year":"2017","unstructured":"Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, et\u00a0al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35(7):785\u201392. https:\/\/doi.org\/10.1200\/JCO.2014.55.3503.","journal-title":"J Clin Oncol."},{"key":"2900_CR19","volume-title":"Updated and consolidated guidelines for programmatic management","author":"Latent tuberculosis infection","year":"2018","unstructured":"Latent tuberculosis infection. Updated and consolidated guidelines for programmatic management. Geneva: World Health Organization (WHO); 2018."},{"issue":"5","key":"2900_CR20","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/cid\/ciw838","volume":"64","author":"MP Cheng","year":"2017","unstructured":"Cheng MP, Chakra CNA, Yansouni CP, Cnossen S, Shrier I, Menzies D, et\u00a0al. Risk of active tuberculosis in patients with cancer: a systematic review and metaanalysis. Clin Infect Dis. 2017;64(5):635\u201344. https:\/\/doi.org\/10.1093\/cid\/ciw838.","journal-title":"Clin Infect Dis."}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-02900-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-021-02900-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-02900-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T08:25:31Z","timestamp":1672734331000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-021-02900-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,8]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2900"],"URL":"https:\/\/doi.org\/10.1186\/s13256-021-02900-8","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,8]]},"assertion":[{"value":"9 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The submission of this case report has been approved by the Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RRM\u2014research involvement: BMS, Lilly, Merck, MSD, Novartis, Roche. Honoraria: BMS, Merck, MSD, Novartis, Roche, Sanofi. Travel grants: BMS, Novartis, Sanofi. All other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"350"}}